A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
Study details include:
Inclusion Criteria:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Phoenix, Arizona 85006, United States
Los Angeles, California 90048, United States
Farmington, Connecticut 06032, United States
Loxahatchee Groves, Florida 33470, United States
Plantation, Florida 33324, United States
Ann Arbor, Michigan 48109, United States
Charlotte, North Carolina 28277, United States
Huntersville, North Carolina 28078, United States
Winston-Salem, North Carolina 27103, United States
DuBois, Pennsylvania 15801, United States
Philadelphia, Pennsylvania 19104, United States
Charleston, South Carolina 29425, United States
Tyler, Texas 75708, United States
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
Porto Alegre, Rio Grande do Sul 91010-006, Brazil
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship 27-400, Poland